Knowledge Hub
Categories:
- Allergy [1]
- Antimicrobials & infection [5]
- Autoimmune [1]
- Chemical Pathology [15]
- Endocrinology [1]
- Epidemiology [3]
- Gastrointestinal [2]
- Genetics [6]
- Genitourinary [2]
- Haematology [9]
- HIV/TB [3]
- Infectious Diseases [10]
- Neurology [4]
- Obstetric and Neonatal care [4]
- Oncology [1]
- Ophthalmology [1]
- Respiratory [2]
- Serology [3]
- Virology [38]
With regard to Designated Service Provider (DSP) Contracts the following law is pertinent for service providers who are not a DSP:
- In terms of Section 59 (2) of the Medical Schemes Act 131 of 1998 the medical scheme must pay valid invoices within 30 days of receipt thereof or advise both the member and service provider of reasons why the invoice is not valid and provide the opportunity to correct the invoice.
- Where services are in respect of medical emergencies or involuntarily obtained services for PMB conditions, the scheme has to pay for the full cost of the services provided without deduction or co-payment or limiting the tariff amount. (Regulation 8 (1) of the Medical Schemes Act no. 131 of 1998.)
- DOH notice 214 of 2021 requires that a scheme pays for services provided at the same rate and in terms of the same rules as they pay their DSPs in respect of services voluntarily obtained, whether they are PMBs or not.
- The process followed in respect of appointing a DSP is required to be fair, equitable, transparent, competitive or cost effective as required in terms of Notice 214 of the DOH.
In summary:
- The law protects the patient’s choice to use their laboratory of choice, even if it is not a DSP, and the scheme is still obliged to reimburse us at the scheme rate for valid claims.
- This is true for PMB conditions as well as non-PMB conditions.
- The medical scheme must pay valid invoices within 30 days or advise both the member and service provider of reasons why the invoice is not valid and provide the opportunity to correct invoice.
- A scheme must pay for the services provided at a tariff not less than what they would pay a DSP.
- Should any patient have a valid claim rejected because we are not a DSP, we can assist.
Respiratory Pathogen Statistics: October 2024
This report is a summary of the results obtained from various molecular respiratory panels performed across PathCare laboratories during October 2024
Gastro-intestinal pathogen statistics
In this report we present laboratory-based data for all GIT molecular panels requested for patients at PathCare laboratories for the last two quarters (March to August 2024).
Respiratory pathogen statistics: September 2025
This report is a summary of the results obtained from various molecular respiratory panels performed across PathCare laboratories during September 2024
Precision Anti-PLA2R Quantification for Membranous Nephropathy
Membranous Nephropathy (MN) is among the most common causes of nephrotic syndrome in adults without diabetes
Stand Alone Molecular Testing for PIC3CA/AKT1
Testing for PIK3CA and AKT1 mutations in tumors is important for several reasons, especially in the context of personalized medicine and targeted cancer therapy.
Respiratory pathogen statistics: August 2024
This report is a summary of the results obtained from various molecular respiratory panels performed across PathCare laboratories during August 2024
Serological Testing for Autoimmune Bullous Dermatoses
Autoimmune bullous skin disease (AIBD) is a group of blistering skin disorders caused by autoantibodies directed against various structural proteins of the skin.
Respiratory Pathogen Statistics: July 2024
This report is a summary of the results obtained from various molecular respiratory panels performed across PathCare laboratories during July 2024
Respiratory Pathogen Statistics: June 2024
This report is a summary of the results obtained from various molecular respiratory panels performed across PathCare laboratories during June 2024